Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-06-08 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
第三届监事会第七次会议决议公告（通讯表决）
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board (监事会) of 福安药业 (Fuan Pharmaceutical) regarding the resolutions passed in their seventh meeting of the third supervisory board. It includes approval of the use of surplus raised funds to supplement working capital and the nomination of a new supervisor to fill a vacancy. The document contains no financial statements or detailed financial data, but rather reports on board-level decisions and personnel changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document length is short (1379 characters), and it is not an annual or interim report, nor an earnings release or regulatory filing. Therefore, the best classification is MANG with high confidence.
2016-06-08 Chinese
第三届董事会第八次会议决议公告（现场表决和通讯表决相结合方式）
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the third board of directors' eighth meeting of the company 福安药业（集团）股份有限公司. It includes details about the meeting date, attendance, voting results, and references to related announcements published on the China Securities Regulatory Commission designated information disclosure website. The content focuses on board meeting decisions and voting outcomes rather than full financial data or detailed reports. The document length is short (870 characters), and it is clearly a board meeting resolution announcement. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors.
2016-06-08 Chinese
关于为全资子公司使用银行授信融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 福安药业（集团）股份有限公司 regarding providing a guarantee for a bank credit financing to its wholly-owned subsidiary. It details the guarantee amount, terms, approval by the board, financial data of the subsidiary, and opinions from independent directors and the supervisory board. There are no financial statements or comprehensive financial performance data presented, nor is this a report or presentation. The document is a formal announcement about a capital/financing activity (providing guarantee for financing). Therefore, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about the financing guarantee, not just a brief notice or report publication announcement.
2016-05-25 Chinese
关于烟台只楚药业有限公司2015年度业绩承诺实现情况的说明
Regulatory Filings Classification · 95% confidence The document is a detailed explanation regarding the performance commitment achievement of Yantai Zhichu Pharmaceutical Co., Ltd. for the year 2015, related to a major asset restructuring transaction by Fuan Pharmaceutical (Group) Co., Ltd. It includes information about the asset purchase, shareholder agreements, compensation mechanisms, and audited financial results for the specific year 2015. The document references regulatory compliance with the China Securities Regulatory Commission's rules on major asset restructuring. It is not a full annual report or interim report but rather a specific disclosure related to a transaction and its performance commitments. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about a transaction and performance commitments, not a full financial report or earnings release. The document length is 3635 characters, which is substantial but not a full financial report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2016-05-25 Chinese
关于烟台只楚药业有限公司2015年度业绩承诺实现情况的说明之审核报告
Audit Report / Information Classification · 95% confidence The document is an audit report issued by Beijing Yongtuo Certified Public Accountants LLP regarding the 2015 performance commitment realization of Yantai Zhichu Pharmaceutical Co., Ltd., a subsidiary of Fuan Pharmaceutical Group Co., Ltd. It includes the auditor's responsibility, management's responsibility, audit opinion, and detailed financial performance related to the asset acquisition and performance commitments. The document references compliance with Chinese securities regulations and contains an auditor's opinion on the fairness of the performance commitment realization. It is a standalone audit report focused on verifying the achievement of performance commitments related to a major asset restructuring transaction, not a full annual report or interim report. The document length is about 4984 characters, which is sufficient for a detailed audit report. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2015
2016-05-25 Chinese
关于以自有资产抵押申请银行贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's use of its own assets as collateral to apply for a bank loan. It details the loan amount, collateral assets, and board approval but does not contain financial statements or detailed financial performance data. The document is relatively short (1759 characters) and serves as a disclosure of a financing activity rather than a full financial report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2016-05-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.